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Introduction
Treatment with steroids for short term cluster headache
(CH) prophylaxis is a widely accepted therapy. However,
the mechanism of action of steroids in CH prophylaxis is
unknown. Various studies could show that the trigemino-
vascular system and the hypothalamus play probably a key
role in CH pathophysiology. The neuropeptid calcitonin
gene related peptide (CGRP) is released in an acute attack
indicating activation of the trigeminovasclular system.[1]
The hypothalamus regulates the circadian secretion of mel-
atonin which is reduced in CH patients during a bout.[2]
Objective
The aim of this study was to assess if treatment with
high dose methylprednisolone (MP) i.v. inhibits release
of CGRP and influences secretion of melatonin in CH.
Methods
10 patients with episodic Cluster headache and 5 control
patients with an acute episode of multiple sclerosis (MS)
who should receive MP i.v. were included in the study.
Patients were treated at the beginning of an episode (CH
or MS) with a course of once daily 1g MP i.v. for three
days followed by oral tapering. CGRP was assessed in
plasma of the external jugular vein and the metabolite of
melatonin in urine - 6-sulfatoxymelatonin – was col-
lected separately during the day and night. Measure-
ments were done before as well as one day, one and two
weeks after start of treatment. Patients recorded the
number and severity of headache attacks each day.
Results
Treatment with MP led to a transient and significant
decline of headache frequency. Simultaneously, CGRP
plasma levels were reduced up to one week after end of
treatment. Secretion of melatonin increased one and
two weeks after treatment significantly. No significant
changes could be observed in the control group.
Conclusion
The results could point to a possible mechanism of action
of steroids in cluster headache prophylaxis. The altered
secretion pattern could be explained through a direct
effect of MP on the trigeminovascular system and the
hypothalamus but could also be a consequence of the
reduced frequency of attacks.
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